2010Zhongguo yaolixue tongbaoRequires access

Simvastatin prevents hypertrophy and keeps cardiac function in myocardium of rabbit with overlord by promoting PPAR gamma and inhibiting NF-kappa B

Wenping Jiang

Open publisher page 0 citations

Abstract

Aim To observe the effects of simvastatin on PPARγ and p65 subunit of NF-κB and to invest the mechanism of simvastatin preventing hypertrophy and keeping cardiac function. Methods 24 rabbits were divided into 4 groups. Rabbits received sham operation as health control in group I. In other groups,aortic regurgitation and coarctation of ascending aorta were operated in rabbits. Rabbits received no drugs in Group Ⅱ. In group Ⅲ,rabbits were given simvastatin 5 mg ·kg-1·d-1 after the operation for 8 weeks. In group Ⅳ,rabbits were given simvastatin 5 mg·kg-1·d-1 after 4 weeks of operation for 4 weeks. At the beginning and the end of the experiment,left ventricular end diastolic pressure (LVEDP) was measured with catheter. At the end of the experiment, heart weight (HW),left ventricular weight (LVW),body weight (BW),heart weight/body weight radio (HW/BW radio), left ventricular weight/body weight radio (LVW/BW radio) were measured. The PPARγ mRNA expression was analyzed by RT-PCR. PPARγ and p65 protein expression in cardiomyocyte nuclear were analyzed through Western blot. The activity of p65 was analyzed with EMSA. Results The HW,LVW,HW/BW were significantly decreased in the early and late treatment group than in CHF group (P0.05,P0.01). The LVW/BW was significantly decreased in early treatment group than in CHF group,too (P0.01). The LVEDP was significantly decreased in the early and late treatment group than in CHF group (P0.01). The mRNA and protein of PPARγ significantly fell in CHF heart (P0.01). The activity and protein expression of p65 were significantly increased in CHF heart (P0. 01). Simvastatin increased the mRNA and protein expression of PPARγ and decreased the ac-tivity and protein expression of p65 (P0.01). Conclusions Simvastatin inhibits the cardiac hypertrophy and improves cardiac function. The mechanism of simvastatin on cardiac remodeling and function relates to the increase of PPARγ expression and preventing the NF-κB activation.

About this research paper

What this paper is about

Aim To observe the effects of simvastatin on PPARγ and p65 subunit of NF-κB and to invest the mechanism of simvastatin preventing hypertrophy and keeping cardiac function. Methods 24 rabbits were divided into 4 groups. Rabbits received sham operation as health control in group I. In other groups,aortic regurgitation and coarctation of ascending aorta were operated in rabbits. Rabbits received no drugs in Group Ⅱ. In group Ⅲ,rabbits were given simvastatin 5 mg ·kg-1·d-1 after the operation for 8 weeks. In group Ⅳ,rabbits were given simvastatin 5 mg·kg-1·d-1 after 4 weeks of operation for 4 weeks. At the beginning and the end of the experiment,left ventricular end diastolic pressure (LVEDP) was measured with catheter. At the end of the experiment, heart weight (HW),left ventricular weight (LVW),body weight (BW),heart weight/body weight radio (HW/BW radio), left ventricular weight/body weight radio (LVW/BW radio) were measured. The PPARγ mRNA expression was analyzed by RT-PCR. PPARγ and p65 protein expression in cardiomyocyte nuclear were analyzed through Western blot. The activity of p65 was analyzed with EMSA. Results The HW,LVW,HW/BW were significantly decreased in the early and late treatment group than in CHF group (P0.05,P0.01). The LVW/BW was significantly decreased in early treatment group than in CHF group,too (P0.01). The LVEDP was significantly decreased in the early and late treatment group than in CHF group (P0.01). The mRNA and protein of PPARγ significantly fell in CHF heart (P0.01). The activity and protein expression of p65 were significantly increased in CHF heart (P0. 01). Simvastatin increased the mRNA and protein expression of PPARγ and decreased the ac-tivity and protein expression of p65 (P0.01). Conclusions Simvastatin inhibits the cardiac hypertrophy and improves cardiac function. The mechanism of simvastatin on cardiac remodeling and function relates to the increase of PPARγ expression and preventing the NF-κB activation.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Aim To observe the effects of simvastatin on PPARγ and p65 subunit of NF-κB and to invest the mechanism of simvastatin preventing hypertrophy and keeping cardiac function. Methods 24 rabbits were divided into 4 groups. Rabbits received sham operation as health control in group I. In other groups,aortic regurgitation and coarctation of ascending aorta were operated in rabbits. Rabbits received no drugs in Group Ⅱ. In group Ⅲ,rabbits were given simvastatin 5 mg ·kg-1·d-1 after the operation for 8 weeks. In group Ⅳ,rabbits were given simvastatin 5 mg·kg-1·d-1 after 4 weeks of operation for 4 weeks. At the beginning and the end of the experiment,left ventricular end diastolic pressure (LVEDP) was measured with catheter. At the end of the experiment, heart weight (HW),left ventricular weight (LVW),body weight (BW),heart weight/body weight radio (HW/BW radio), left ventricular weight/body weight radio (LVW/BW radio) were measured. The PPARγ mRNA expression was analyzed by RT-PCR. PPARγ and p65 protein expression in cardiomyocyte nuclear were analyzed through Western blot. The activity of p65 was analyzed with EMSA. Results The HW,LVW,HW/BW were significantly decreased in the early and late treatment group than in CHF group (P0.05,P0.01). The LVW/BW was significantly decreased in early treatment group than in CHF group,too (P0.01). The LVEDP was significantly decreased in the early and late treatment group than in CHF group (P0.01). The mRNA and protein of PPARγ significantly fell in CHF heart (P0.01). The activity and protein expression of p65 were significantly increased in CHF heart (P0. 01). Simvastatin increased the mRNA and protein expression of PPARγ and decreased the ac-tivity and protein expression of p65 (P0.01). Conclusions Simvastatin inhibits the cardiac hypertrophy and improves cardiac function. The mechanism of simvastatin on cardiac remodeling and function relates to the increase of PPARγ expression and preventing the NF-κB activation.

Key concepts: Simvastatin, Preload, Internal medicine, Endocrinology, Medicine, Body weight, Western blot, Cardiac function curve

Related papers

Back to paper searchBrowse research topicsOriginal source
Simvastatin prevents hypertrophy and keeps cardiac function in myocardium of rabbit with overlord by promoting PPAR gamma and inhibiting NF-kappa B — Research Paper | ScholarLens